Skip to main
CGON
CGON logo

CGON Stock Forecast & Price Target

CGON Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 50%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

CG Oncology Inc. is positioned for significant revenue growth, with projected launch sales of its candidate, cretostimogene grenadenorepvec, anticipated to reach approximately $2.6 billion by 2034. The company's emphasis on differentiated efficacy and durability, as suggested by the promising data from its clinical trials, indicates strong potential for treatment adoption among physicians and patients, addressing the unmet need for next-generation therapies targeting NMIBC. Additionally, the successful navigation of regulatory pathways and management's confidence in manufacturing readiness further strengthens the outlook for Creto's commercialization and market presence.

Bears say

The financial analysis highlights several concerns regarding CG Oncology's stock, primarily focusing on competitive positioning and potential market risks. The history of other oncology products, such as Zaltrap against Avastin, indicates that lack of differentiation in effectiveness can lead to poor market performance, which could equally affect CG Oncology if its therapy does not demonstrate substantial advantages. Additionally, the risk of negative trial outcomes, slow enrollment, and potential regulatory hurdles raises serious doubts about the company’s timeline for commercialization and market potential, further undermining investor confidence.

CGON has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 50% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CG oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CG oncology Inc (CGON) Forecast

Analysts have given CGON a Buy based on their latest research and market trends.

According to 10 analysts, CGON has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $61.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $61.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CG oncology Inc (CGON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.